Diabetes & Metabolism Journal (Aug 2019)
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
- Mee Kyoung Kim,
- Seung-Hyun Ko,
- Bo-Yeon Kim,
- Eun Seok Kang,
- Junghyun Noh,
- Soo-Kyung Kim,
- Seok-O Park,
- Kyu Yeon Hur,
- Suk Chon,
- Min Kyong Moon,
- Nan-Hee Kim,
- Sang Yong Kim,
- Sang Youl Rhee,
- Kang-Woo Lee,
- Jae Hyeon Kim,
- Eun-Jung Rhee,
- SungWan Chun,
- Sung Hoon Yu,
- Dae Jung Kim,
- Hyuk-Sang Kwon,
- Kyong Soo Park,
Affiliations
- Mee Kyoung Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, .Korea
- Seung-Hyun Ko
- Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, .Korea
- Bo-Yeon Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, .Korea
- Eun Seok Kang
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, .Korea
- Junghyun Noh
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, .Korea
- Soo-Kyung Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, .Korea
- Seok-O Park
- Gwangmyeong Sungae Hospital, Gwangmyeong, .Korea
- Kyu Yeon Hur
- Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, .Korea
- Suk Chon
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, .Korea
- Min Kyong Moon
- Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, .Korea
- Nan-Hee Kim
- Department of Internal Medicine, Korea University College of Medicine, Ansan, .Korea
- Sang Yong Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, .Korea
- Sang Youl Rhee
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, .Korea
- Kang-Woo Lee
- Sejong St. Mary's Diabetes and Endocrine Clinic, Sejong, .Korea
- Jae Hyeon Kim
- Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, .Korea
- Eun-Jung Rhee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, .Korea
- SungWan Chun
- Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, .Korea
- Sung Hoon Yu
- Department of Endocrinology and Metabolism, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, .Korea
- Dae Jung Kim
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, .Korea
- Hyuk-Sang Kwon
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, .Korea
- Kyong Soo Park
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, .Korea
- DOI
- https://doi.org/10.4093/dmj.2019.0137
- Journal volume & issue
-
Vol. 43,
no. 4
pp. 398 – 406
Abstract
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.
Keywords
